Eli Lilly and Co. recently announced that it’s spending $1 billion to expand its Limerick, Ireland, manufacturing site. The goal of the expansion, announced Sept. 12, is to increase the production of biologic active ingredients, including those for the company’s recently approved treatment for early symptomatic Alzheimer’s disease. The company announced in July that the…
CMS will limit coverage of Aduhelm to people in clinical trials
The Centers for Medicare & Medicaid Services (CMS) released a national policy regarding coverage for Aduhelm (aducanumab). Controversy has surrounded the Alzheimer’s drug Aduhelm from Biogen (NSDQ:BIIB) and Eisai (TYO:4523) since the FDA’s fast track approval last year. Three members of an FDA advisory committee resigned after the approval. About a week later, nonprofit watchdog group Public Citizen called for high-profile resignations of…
Senate Finance Committee senators call for hearing on Medicare coverage of aducanumab
Senate finance Committee members Elizabeth Warren (D-MA) and Bill Cassidy (R-LA) are pushing to have a hearing to discuss the Medicare coverage of Aduhelm (aducanumab), Biogen’s controversial Alzheimer’s treatment, which recently won FDA approval. In a letter addressed to Senate Finance chair Ron Wyden (D-OR) and ranking member Mike Crapo (R-ID), Warren and Cassidy express…